• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Med Sci . Liver Injury in Patients with COVID-19: A Retrospective Study

tetano

Editor, Senior Moderator
Int J Med Sci


. 2023 Feb 5;20(3):385-391.
doi: 10.7150/ijms.81214. eCollection 2023.
Liver Injury in Patients with COVID-19: A Retrospective Study


Yun Feng[SUP] 1 [/SUP], Yaping Liu[SUP] 1 [/SUP], Qian Zhao[SUP] 1 [/SUP], Jiao Zhu[SUP] 1 [/SUP], Xiaona Kang[SUP] 1 [/SUP], Chen Mi[SUP] 1 [/SUP], Peijie Li[SUP] 1 [/SUP], Weizhi Li[SUP] 1 [/SUP], Guifang Lu[SUP] 1 [/SUP], Ai Jia[SUP] 1 [/SUP], Shuixiang He[SUP] 1 [/SUP], Hongxia Li[SUP] 1 [/SUP]



Affiliations

Abstract

Objectives: The objective of this study is to explore the incidence, characteristics, risk factors, and prognosis of liver injury in patients with COVID-19. Methods: We collected clinical data of 384 cases of COVID-19 and retrospectively analyzed the incidence, characteristics, and risk factors of liver injury of the patients. In addition, we followed the patient two months after discharge. Results: A total of 23.7% of the patients with COVID-19 had liver injury, with higher serum AST (P < 0.001), ALT (P < 0.001), ALP (P = 0.004), GGT (P < 0.001), total bilirubin (P = 0.002), indirect bilirubin (P = 0.025) and direct bilirubin (P < 0.001) than the control group. The median serum AST and ALT of COVID-19 patients with liver injury were mildly elevated. Risk factors of liver injury in COVID-19 patients were age (P = 0.001), history of liver diseases (P = 0.002), alcoholic abuse (P = 0.036), body mass index (P = 0.037), severity of COVID-19 (P < 0.001), C-reactive protein (P < 0.001), erythrocyte sedimentation rate (P < 0.001), Qing-Fei-Pai-Du-Tang treatment (P = 0.032), mechanical ventilation (P < 0.001), and ICU admission (P < 0.001). Most of the patients (92.3%) with liver injury were treated with hepatoprotective drugs. 95.6% of the patients returned to normal liver function tests at 2 months after discharge. Conclusions: Liver injury was commen in COVID-19 patients with risk factors, most of them have mild elevations in transaminases, and conservative treatment has a good short-term prognosis.

Keywords: COVID-19; Chinese traditional medicine; Severe Acute Respiratory Syndrome Coronavirus 2; liver function tests; liver injury.
 
Back
Top Bottom